Invitation to Devyser’s Capital Markets Day

Devyser invites investors, analysts and media to a Capital Markets Day on Monday, November 25, 2024 at the company's headquarters in Årsta, Stockholm.

The program will include presentations by the Devyser executive management team as well as key external speakers. During the day, the audience will have the opportunity to ask questions. There will also be the option to join a tour of the company's new headquarters and production unit.

The Capital Markets Day will be held in English. The agenda and more detailed information will be announced closer to the event. 

Location: Devyser (HQ), Bränningevägen 12, Årsta, Stockholm, Sweden
Date: Monday, November 25, 2024
Time: 13:30-16:00 followed by an optional tour of the new facilities. The venue opens at 13:00.

There are limited seats at the event so make sure to reserve your seat via the registration below if you want to attend in person.

https://ir.financialhearings.com/devyser-cmd-2024

The last day to register is Friday, November 22, 2024.

The event will also be available online on-demand once the on-site event has been concluded (approx at 17:30 CET).

For more information, please contact:
Fredrik Alpsten, CEO 
Email: [email protected]
Telephone: +46 8 562 158 50
 
Sabina Berlin, CFO 
Email: [email protected] 
Telephone: +46 8 562 158 50

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB. 

For more information, visit www.devyser.com.